

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CONCORD HEALTHCARE GROUP CO., LTD.\***

**美中嘉和醫學技術發展集團股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2453)**

### **INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY**

This announcement is made by Concord Healthcare Group Co., Ltd.\* (美中嘉和醫學技術發展集團股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

Reference is made to the Guidelines on Application for “Full Circulation” of Domestic Unlisted Shares of H-share Companies (《H股公司境內未上市股份申請“全流通”業務指引》) issued by the China Securities Regulatory Commission (the “**CSRC**”) on November 14, 2019 and further amended on August 10, 2023 (the “**Guidelines**”) regarding the procedures of application by companies whose H shares are listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.

In view of the Guidelines, the board of directors (the “**Board**”) of the Company is pleased to announce that on April 30, 2024, the Company has submitted an application to the CSRC in respect of the conversion of certain outstanding domestic shares (“**Domestic Shares**”) of the Company with par value of RMB1.00 per share into H shares (“**H Shares**”) of the Company with par value of RMB1.00 per share that are listed on the main board of the Stock Exchange (the “**H Share Full Circulation**”). Upon obtaining all the relevant approvals (including the filings with and/or approvals from the CSRC and the Stock Exchange) and having complied with all the applicable laws, regulations and rules, such Domestic Shares will be converted into H Shares (the “**Conversion**”), and the Company will apply for the listing of and permission to deal in such H Shares on the main board of the Stock Exchange (the “**Listing**”). Pursuant to the articles of association of the Company, no further shareholders’ meeting is required to be convened to approve the Conversion and the Listing shall comply with the procedures, regulations and requirements of the Stock Exchange.

As at the date of this announcement, the details of the Company's implementation plan of the Conversion and the Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and the Listing in compliance with the Listing Rules and/or the Inside Information Provisions as and when appropriate.

**The H Share Full Circulation and the completion of the Conversion and the Listing is subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other relevant onshore and offshore regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Concord Healthcare Group Co., Ltd.\***  
美中嘉和醫學技術發展集團股份有限公司  
**YANG Jianyu**  
*Chairman and Executive Director*

The PRC, April 30, 2024

*As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao, Mr. CHANG Liang and Mr. SHI Botao as executive directors of the Company; (ii) Mr. WANG Lei and Mr. CHEN Hongzhang as non-executive directors of the Company; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive directors of the Company.*

\* *For identification purposes only*